DBV Technologies (DBVT) Research & Development (2020 - 2026)
DBV Technologies (DBVT) posted Research & Development of $31.2 million for Q2 2026, down 6.59% sequentially from $33.4 million in Q1 2026, and down 7.42% YoY from $33.7 million in Q2 2025.
DBV Technologies (DBVT) Research & Development (2020 - 2026) Analysis & Trends
DBV Technologies has reported Research & Development for 7 years, with the latest figure at $31.2 million in Q2 2026.
- Quarterly Research & Development fell 7.42% year-over-year to $31.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $126.1 million (up 28.99% YoY) and the FY2025 annual result came in at $116.7 million, up 30.6% from the prior year.
- Research & Development fell to $31.2 million in Q2 2026 per DBVT's latest filing, from $33.4 million in the prior quarter.
- Over five years, Research & Development peaked at $33.7 million in Q2 2025 and troughed at $12.2 million in Q1 2022.
- A 5-year average of $22.6 million and a median of $21.5 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2023: Research & Development soared 153.69% in 2022, then sank 56.86% in 2023.
- Over 5 years, Research & Development stood at $29.6 million in 2022, then tumbled by 56.86% to $12.8 million in 2023, then soared by 47.98% to $18.9 million in 2024, then soared by 73.99% to $32.9 million in 2025, then retreated by 5.14% to $31.2 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $31.2 million, $33.4 million, and $32.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - | 31.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.20 Mn |
| Mar 31, 2026 | 33.40 Mn |
| Dec 31, 2025 | 32.89 Mn |
| Sep 30, 2025 | 28.62 Mn |
| Jun 30, 2025 | 33.70 Mn |
| Mar 31, 2025 | 21.50 Mn |
| Dec 31, 2024 | 18.90 Mn |
| Sep 30, 2024 | 23.66 Mn |
| Jun 30, 2024 | 25.37 Mn |
| Mar 31, 2024 | 21.40 Mn |
| Dec 31, 2023 | 12.78 Mn |
| Sep 30, 2023 | 13.80 Mn |
| Jun 30, 2023 | 17.62 Mn |
| Mar 31, 2023 | 16.04 Mn |
| Dec 31, 2022 | 29.61 Mn |
| Sep 30, 2022 | 15.10 Mn |
| Jun 30, 2022 | 18.61 Mn |
| Mar 31, 2022 | 12.22 Mn |
| Dec 31, 2021 | 11.67 Mn |
| Sep 30, 2021 | 16.32 Mn |